Forastiere Arlene A
Johns Hopkins University School of Medicine, Department of Oncology, Baltimore, Maryland 21231, USA.
J Surg Oncol. 2008 Jun 15;97(8):701-7. doi: 10.1002/jso.21012.
Three decades of collaborative research have led to the integration of platinum-based chemotherapy into the curative management of squamous cell carcinoma of the head and neck and gains in local-regional control, organ preservation and survival endpoints. Concomitant cisplatin-based chemotherapy and radiotherapy is the strategy that has proven most effective for organ preservation for larynx and oropharynx cancers, the treatment of unresectable disease, nasopharyngeal cancer and the post-operative adjuvant treatment of patients at high risk of recurrence. The evolution of current indications for this multimodality approach is reviewed and current areas of investigation discussed. Nearly all patients with locally advanced head and neck cancer receive chemotherapy as part of initial curative treatment. The focus of future trials should be on survival improvement, toxicity reduction and risk stratification for treatment decision making.
三十年的合作研究已使铂类化疗被纳入头颈部鳞状细胞癌的根治性治疗方案中,并在局部区域控制、器官保留和生存终点方面取得了进展。基于顺铂的同步放化疗是已被证明对喉癌和口咽癌的器官保留、不可切除疾病的治疗、鼻咽癌以及复发高危患者的术后辅助治疗最有效的策略。本文回顾了这种多模式治疗方法当前适应证的演变,并讨论了当前的研究领域。几乎所有局部晚期头颈部癌患者都接受化疗作为初始根治性治疗的一部分。未来试验的重点应是提高生存率、降低毒性以及为治疗决策进行风险分层。